These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States. J Pharmacokinet Biopharm; 1974 Oct; 2(5):433-66. PubMed ID: 4452945 [No Abstract] [Full Text] [Related]
5. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy. Simmons HE Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901 [No Abstract] [Full Text] [Related]
6. FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages. Hunnisett-Dritz D Am J Health Syst Pharm; 2012 Oct; 69(19):1626, 1628. PubMed ID: 22997113 [No Abstract] [Full Text] [Related]
7. A history of biopharmaceutics in the Food and Drug Administration 1968-1993. Skelly JP AAPS J; 2010 Mar; 12(1):44-50. PubMed ID: 19936940 [TBL] [Abstract][Full Text] [Related]
8. Assuring total drug quality. Simmons HE J Am Pharm Assoc; 1973 Feb; 13(2):96-8. PubMed ID: 4686621 [No Abstract] [Full Text] [Related]
9. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements. Davit BM; Kanfer I; Tsang YC; Cardot JM AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914 [TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Greed and Its Consequences. Jacobs HE Conn Med; 2016 May; 80(5):315-6. PubMed ID: 27328583 [No Abstract] [Full Text] [Related]
11. Statement of the APhA to the Subcommittee on Health United States Senate. 93rd Congress, 2nd session, Washington, D.C., July 22, 1974. Apple WS J Am Pharm Assoc; 1974 Oct; 14(10):572-6. PubMed ID: 4419654 [No Abstract] [Full Text] [Related]
12. Drug development, regulation, and the practice of medicine. Wardell WM JAMA; 1974 Sep; 229(11):1457-61. PubMed ID: 4408186 [No Abstract] [Full Text] [Related]
13. World's drug supply chain needs better oversight, FDA says. Traynor K Am J Health Syst Pharm; 2009 Jan; 66(1):12-3. PubMed ID: 19106338 [No Abstract] [Full Text] [Related]
14. Editorial: Bioequivalence and drug product selection. Zellmer WA Am J Hosp Pharm; 1974 Oct; 31(10):931. PubMed ID: 4440688 [No Abstract] [Full Text] [Related]
15. Not as easy as it may appear: using radio frequency identification technology to fulfill the Prescription Drug Marketing Act's elusive pedigree requirement. Asamoah AK Food Drug Law J; 2006; 61(2):385-418. PubMed ID: 16903035 [No Abstract] [Full Text] [Related]
16. Importance of biopharmaceutics and pharmacokinetics in clinical medicine. Cabana BE Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194 [TBL] [Abstract][Full Text] [Related]
17. Securing the US pharmaceutical supply. Somberg JC Am J Ther; 2008; 15(3):197. PubMed ID: 18496255 [No Abstract] [Full Text] [Related]
18. ASHP, other groups, advise FDA about solving counterfeit drug problems. Young D Am J Health Syst Pharm; 2003 Dec; 60(23):2406, 2408, 2411. PubMed ID: 14686215 [No Abstract] [Full Text] [Related]